Cargando…

Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study

OBJECTIVE: The aim was to characterize the electrophysiological features and plasma biomarkers of critical illness polyneuropathy (CIN) and myopathy (CIM) in coronavirus disease 2019 (COVID-19) patients with intensive care unit acquired weakness (ICUAW). METHODS: An observational ICU cohort study in...

Descripción completa

Detalles Bibliográficos
Autores principales: Frithiof, Robert, Rostami, Elham, Kumlien, Eva, Virhammar, Johan, Fällmar, David, Hultström, Michael, Lipcsey, Miklós, Ashton, Nicholas, Blennow, Kaj, Zetterberg, Henrik, Punga, Anna Rostedt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Federation of Clinical Neurophysiology. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012169/
https://www.ncbi.nlm.nih.gov/pubmed/33875374
http://dx.doi.org/10.1016/j.clinph.2021.03.016
_version_ 1783673325770244096
author Frithiof, Robert
Rostami, Elham
Kumlien, Eva
Virhammar, Johan
Fällmar, David
Hultström, Michael
Lipcsey, Miklós
Ashton, Nicholas
Blennow, Kaj
Zetterberg, Henrik
Punga, Anna Rostedt
author_facet Frithiof, Robert
Rostami, Elham
Kumlien, Eva
Virhammar, Johan
Fällmar, David
Hultström, Michael
Lipcsey, Miklós
Ashton, Nicholas
Blennow, Kaj
Zetterberg, Henrik
Punga, Anna Rostedt
author_sort Frithiof, Robert
collection PubMed
description OBJECTIVE: The aim was to characterize the electrophysiological features and plasma biomarkers of critical illness polyneuropathy (CIN) and myopathy (CIM) in coronavirus disease 2019 (COVID-19) patients with intensive care unit acquired weakness (ICUAW). METHODS: An observational ICU cohort study including adult patients admitted to the ICU at Uppsala University Hospital, Uppsala, Sweden, from March 13th to June 8th 2020. We compared the clinical, electrophysiological and plasma biomarker data between COVID-19 patients who developed CIN/CIM and those who did not. Electrophysiological characteristics were also compared between COVID-19 and non-COVID-19 ICU patients. RESULTS: 111 COVID-19 patients were included, 11 of whom developed CIN/CIM. Patients with CIN/CIM had more severe illness; longer ICU stay, more thromboembolic events and were more frequently treated with invasive ventilation for longer than 2 weeks. In particular CIN was more frequent among COVID-19 patients with ICUAW (50%) compared with a non-COVID-19 cohort (0%, p = 0.008). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAp) levels were higher in the CIN/CIM group compared with those that did not develop CIN/CIM (both p = 0.001) and correlated with nerve amplitudes. CONCLUSIONS: CIN/CIM was more prevalent among COVID-19 ICU patients with severe illness. SIGNIFICANCE: COVID-19 patients who later developed CIN/CIM had significantly higher NfL and GFAp in the early phase of ICU care, suggesting their potential as predictive biomarkers for CIN/CIM.
format Online
Article
Text
id pubmed-8012169
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Federation of Clinical Neurophysiology. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-80121692021-04-01 Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study Frithiof, Robert Rostami, Elham Kumlien, Eva Virhammar, Johan Fällmar, David Hultström, Michael Lipcsey, Miklós Ashton, Nicholas Blennow, Kaj Zetterberg, Henrik Punga, Anna Rostedt Clin Neurophysiol Article OBJECTIVE: The aim was to characterize the electrophysiological features and plasma biomarkers of critical illness polyneuropathy (CIN) and myopathy (CIM) in coronavirus disease 2019 (COVID-19) patients with intensive care unit acquired weakness (ICUAW). METHODS: An observational ICU cohort study including adult patients admitted to the ICU at Uppsala University Hospital, Uppsala, Sweden, from March 13th to June 8th 2020. We compared the clinical, electrophysiological and plasma biomarker data between COVID-19 patients who developed CIN/CIM and those who did not. Electrophysiological characteristics were also compared between COVID-19 and non-COVID-19 ICU patients. RESULTS: 111 COVID-19 patients were included, 11 of whom developed CIN/CIM. Patients with CIN/CIM had more severe illness; longer ICU stay, more thromboembolic events and were more frequently treated with invasive ventilation for longer than 2 weeks. In particular CIN was more frequent among COVID-19 patients with ICUAW (50%) compared with a non-COVID-19 cohort (0%, p = 0.008). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAp) levels were higher in the CIN/CIM group compared with those that did not develop CIN/CIM (both p = 0.001) and correlated with nerve amplitudes. CONCLUSIONS: CIN/CIM was more prevalent among COVID-19 ICU patients with severe illness. SIGNIFICANCE: COVID-19 patients who later developed CIN/CIM had significantly higher NfL and GFAp in the early phase of ICU care, suggesting their potential as predictive biomarkers for CIN/CIM. International Federation of Clinical Neurophysiology. Published by Elsevier B.V. 2021-07 2021-04-01 /pmc/articles/PMC8012169/ /pubmed/33875374 http://dx.doi.org/10.1016/j.clinph.2021.03.016 Text en © 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Frithiof, Robert
Rostami, Elham
Kumlien, Eva
Virhammar, Johan
Fällmar, David
Hultström, Michael
Lipcsey, Miklós
Ashton, Nicholas
Blennow, Kaj
Zetterberg, Henrik
Punga, Anna Rostedt
Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study
title Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study
title_full Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study
title_fullStr Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study
title_full_unstemmed Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study
title_short Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study
title_sort critical illness polyneuropathy, myopathy and neuronal biomarkers in covid-19 patients: a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012169/
https://www.ncbi.nlm.nih.gov/pubmed/33875374
http://dx.doi.org/10.1016/j.clinph.2021.03.016
work_keys_str_mv AT frithiofrobert criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT rostamielham criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT kumlieneva criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT virhammarjohan criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT fallmardavid criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT hultstrommichael criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT lipcseymiklos criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT ashtonnicholas criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT blennowkaj criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT zetterberghenrik criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy
AT pungaannarostedt criticalillnesspolyneuropathymyopathyandneuronalbiomarkersincovid19patientsaprospectivestudy